MSMehrdad Nasrollahzadeh Sabet

Mehrdad Nasrollahzadeh Sabet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehrdad Nasrollahzadeh Sabet has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Bahram Pakzad

    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran

    4 shared publications
  • Emran Esmaeilzadeh

    Fetal Health Research Center, Hope Generation Foundation, Tehran, Iran

    3 shared publications
  • Naeim Ehtesham

    Department of Genetics and Advanced Medical Technology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran

    3 shared publications
  • Behrang Alani

    Department of Applied Cell Sciences, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran

    2 shared publications
  • Meysam Mosallaei

    Personalized Medicine and Genometabolomics Research Center, Hope Generation Foundation, Tehran, Iran

    2 shared publications
  • Mostafa Saghi

    School of medicine, AJA University of Medical Science, Tehran, Iran

    2 shared publications

Latest Publications

  • Significant hypomethylation of MMP9 gene promoter in patients with systemic lupus erythematosus

    by Naeim Ehtesham, Meysam Mosallaei, Morteza Zaboli Mahdiabadi, Taiebe Kenarangi, Arezoo Farhadi, Mohammad Foad Heidari, Mohsen Soroush, Mehrdad Nasrollahzadeh Sabet, Javad Behroozi

    Objective: Scholars are exploring novel diagnostic and prognostic biomarkers with higher sensitivity and specificity for systemic lupus erythematosus (SLE). In this regard, DNA methylation alterations have aroused attention. The association between the dysfunction of MMP9 and TNFAIP3 genes and SLE has been previously demonstrated. Therefore, in this study, we investigated the methylation level of MMP9 and TNFAIP3 promoters in peripheral blood mononuclear cells (PBMCs) of SLE patients and healthy controls. Methods: Eighty Iranian SLE patients and 77 healthy individuals were enrolled. The methylation quantification endonuclease-resistant DNA (MethyQESD) method was used to assess methylation levels of MMP9 and TNFAIP3 in extracted DNA of PBMCs. To quantify the diagnostic utility of the promoter methylation level of these genes, the receiver operating characteristic (ROC) curve was constructed. Results: MMP9 promoter was significantly hypomethylated in SLE patients compared with healthy people ( p < 0.001), while there was no significant difference in terms of TNFAIP3 promoter methylation levels ( p = 0.167). Also, this differential MMP9 methylation was observed in patients with renal involvement and patients without renal involvement (42.07 ± 25.73 vs 56.74 ± 29.71, p = 0.007). ROC analyses indicated that the diagnostic power of the MMP9 promoter methylation level for SLE was 0.839 [95% CI (0.781–0.911)]. Moreover, MMP9 methylation level was negatively correlated with creatinine and anti-dsDNA concentration and positively correlated with C3 and C4 levels. Conclusion: The results of this study highlight the application of MMP9 methylation level in PBMCs of SLE patients as a diagnostic biomarker.


  • Assessment of the association between TNIP1 polymorphism with clinical features and risk of systemic lupus erythematosus

    by Sara Azhdari, Mostafa Saghi, Behrang Alani, Maryam Zare Rafie, Taiebe Kenarangi, Mehrdad Nasrollahzadeh Sabet, Bahram Pakzad, Tahereh Ghorashi, Milad Gholami, Mohsen Soosanabadi

    Objective: Over the past decades, TNIP1 has been identified as a strong risk locus in multiple genome-wide association studies (GWAS), spanning multiple populations and various autoimmune diseases. TNIP1 is a polyubiquitin-binding protein that works as a physiological inhibitor of NF-κB and maintains immune homeostasis. Some studies have confirmed that TNIP1 is downregulated in autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In the current study, for the first time, we evaluated the possible association between rs6889239 polymorphism in the TNIP1 gene with the risk and clinical characteristics of RA and SLE in the Iranian population. Method: In this case–control study, 115 patients with RA, 115 patients with SLE, and 115 unrelated healthy subjects were enrolled to estimate rs6889239 genotypes with real-time PCR high resolution melting (HRM) method. Results: Our results demonstrated considerable associations between CC genotype and C allele of rs6889239 with augmented risk of SLE (OR for CC genotype= 2.23; 95%CI [1.175–4.307], OR for C allele= 1.84; 95%CI [1.254–2.720]). However, there was an insignificant association between genotypes and allele frequencies of rs6889239 with the occurrence risk of RA in the population under study ( p > 0.05). Additionally, stratification analysis specified that the C allele in rs6889239 was linked with the incidence of renal involvement in SLE patients and lower age of onset in the RA group ( p < 0.05). Conclusion: These findings propose a significant association between TNIP1 polymorphism and higher risk of SLE and some clinical characteristics of RA and SLE.


  • Association of a miRNA-binding site polymorphism in IL-16 gene with disease risk and clinical characteristics of rheumatoid arthritis and systemic lupus erythematosus

    by Somayeh Zeinalzadeh, Nahid Kheradmand, Ghazal Rasouli, Emran Esmaeilzadeh, Bahram Pakzad, Javad Behroozi, Mohsen Chamanara, Mojtaba Yousefi Zoshk, Naeim Ehtesham, Mehrdad Nasrollahzadeh Sabet

    Introduction /objectives. Single nucleotide polymorphisms (SNPs) located at the 3′-UTR region of the target genes of microRNAs (miRNAs) can dysregulate their expression via disrupting the binding site of miRNAs. Interleukin-16 (IL-16) is involved in the pathogenesis of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In the current study, we assessed the possible association between rs1131445 polymorphism in IL-16 gene with risk and clinical characteristics of RA and SLE in the Iranian population. Methods In this case–control study, 120 patients with RA, 120 patients with SLE, and 120 unrelated healthy subjects were collected to estimate rs1131445 (T > C) polymorphism in IL-16 gene using real-time PCR high-resolution melting (HRM) method. Results Our results demonstrated considerable associations between TC genotype and C allele of rs1131445 with enhanced risk of RA (ORfor TC genotype = 3.01; 95%CI [1.667–5.526], P < 0.001; ORfor C allele = 1.96; 95%CI [1.314–2.941], P < 0.001). Besides, there was a marginal association between CC genotype and increased risk of RA (P: 0.031). However, there was an insignificant correlation between genotypes and allele frequencies of rs1131445 with incidence risk of SLE (P > 0.05). Moreover, stratification analysis indicated that the C allele in rs1131445 was linked with disease activity–associated laboratory parameters such as CRP and ESR in both RA and SLE patients, as well as the higher incidence of neurological symptoms in SLE subjects (P < 0.05). Conclusion These results proposed a significant association between IL-16 polymorphism and augmented risk of RA and clinical characteristics of RA and SLE. Key Points • Single nucleotide polymorphism (rs1131445) in miRNA -binding sites which is located in 3′ˊUTR of the IL-16 gene could be associated with RA and SLE risk by dysregulation of IL-16 expression. • Our findings proposed a significant association between IL-16 polymorphism and augmented risk of RA and clinical characteristics of RA and SLE


  • Impact of miRNA-binding site polymorphisms in STAT3 gene on occurrence and clinical characteristics of systemic lupus erythematosus

    by Amirhossein Salehi, Mehrdad Nasrollahzadeh Sabet, Emran Esmaeilzadeh, Maryam Mousavi, Jalal Karimi, Bahram Pakzad

    Background: Signal transducer and activator of transcription 3 (STAT3) is a major regulator of immune response and chronic inflammatory conditions acting through regulation of B cells, T-helper 17 (Th17) cells, and IL-17 production. Previous studies have demonstrated that dysregulation of STAT3 is crucial for SLE pathogenesis and disease severity. It is believed that single nucleotide polymorphisms (SNPs) located at the 3′-UTR sequence of the target genes could dysregulate their expression by disrupting the binding site of miRNAs. In the present study, we assessed the possible association between rs1053005 and rs1053023 SNPs at miRNA binding sites in the STAT3 gene and the risk of SLE in the Iranian population for the first time. Methods: 112 SLE cases and 120 healthy controls were genotyped for rs1053005 (A>G) and rs1053023 (A>G) polymorphisms in STAT3 using real-time PCR high resolution melting method (HRM). Results: Our results revealed substantial associations between GG genotype and G allele of rs1053023 with enhanced risk of SLE (OR for GG genotype= 3.13; 95%CI [1.61–6.1], OR for G allele = 2.22; 95%CI [1.51–3.25]). However, no important correlations have been found between rs1053005 polymorphism and SLE susceptibility in this population ( p>0.05). Moreover, stratification analysis showed that these polymorphisms are correlated with parameters indicating disease activity and more severe course of the disease. These factors include some laboratory test results and clinical manifestations such as renal involvements. Conclusion: The current study suggests a significant association between STAT3 polymorphisms and augmented risk of SLE, clinical symptoms, disease activity, and severity.


  • Open Access

    Diagnostic Performance of Chest CT-Scan and First RT-PCR Testing for COVID-19 in Iranian Population

    by Ramin Hamidi Farahani, Meysam Mosallaei, Ebrahim Hazrati, Naeim Ehtesham, Bahram Pakzad, Mehrdad Nasrollahzadeh Sabet, Emran Esmaeilzadeh

    The article's abstract is not available.

  • Strong association of common variants in the miRNA-binding site of NOD2 gene with clinicopathological characteristics and disease activity of systemic lupus erythematosus

    by Emran Esmaeilzadeh, Mostafa Saghi, Mehdi Hassani, Saeideh Davar, Behrang Alani, Bahram Pakzad, Sepideh Ghobakhloo, Sharifeh Khosravi, Mehrdad Nasrollahzadeh Sabet

    Introduction/objectives Systemic lupus erythematosus (SLE) is a multifactorial systemic autoimmune disease, in which genetic susceptibility plays a pivotal role. The nucleotide oligomerization domain 2 (NOD2) gene is one of the main regulators of chronic inflammatory conditions and could be involved in SLE pathogenesis. Single nucleotide polymorphisms (SNPs) in miRNA binding sites which are located in 3′UTR of the NOD2 gene could be associated with SLE risk by dysregulation of NOD2 expression. In the present study, we assessed the possible association between SNPs rs3135500 and rs3135499 in the NOD2 gene with SLE risk in the Iranian population. Methods A case–control study using 110 SLE patients and 120 control subjects was undertaken to estimate rs3135500 (G > A) and rs3135499 (A > C) genotypes via real-time PCR high-resolution melting method (HRM). Results No significant association was observed between allele and genotype frequencies of rs3135500 and rs3135499 polymorphisms and SLE risk in this population (P > 0.05). However, there was an obvious association between rs3135500 (A allele) with laboratory factors that are associated with disease activity (P < 0.05) and some clinical manifestations that are associated with disease severity such as neurological symptoms, skin manifestations, renal involvements, and higher serum concentration of creatinine (P < 0.05). Besides, rs3135499 (C allele) was correlated with renal involvement and also the concentration of creatinine (P < 0.05). Moreover, in the patients group, the risk alleles in these polymorphisms were associated with lower age of onset (P < 0.05). Conclusions Our results suggest a substantial association between NOD2 polymorphisms with clinicopathological characteristics and SLE disease activity. Key Points • Single nucleotide polymorphisms (SNPs) in miRNA binding sites which are located in 3′UTR of the NOD2 gene could be associated with SLE risk by dysregulation of NOD2 expression. • Our results suggested that two miRSNPs (rs3135500 and rs3135499) in the NOD2 gene were meaningfully correlated with clinicopathological characteristics and disease activity of SLE.


  • Open Access

    Shikonin ameliorates experimental autoimmune encephalomyelitis (EAE) via immunomodulatory, anti-apoptotic and antioxidative activity

    by Mehrdad Nasrollahzadeh Sabet, Sajjad Biglari, Hamid Reza Khorram Khorshid, Emran Esmaeilzadeh

    Objectives Multiple sclerosis is a common autoimmune inflammatory disease of the central nervous system. There are several underlying mechanisms for the pathogenesis of the disease, including inflammation, oligodendrocyte apoptosis and oxidative stress. Methods The mechanism of action of shikonin was investigated in the C57BL/6 experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. Key findings The results revealed that EAE induction significantly increased the extent of demyelination in the corpus callosum tissues of the animals, while treatment of the mice with shikonin significantly decreased the extent of demyelination. Real‐time polymerase chain reaction‐based analysis of the brain samples from the EAE mice revealed significant enhancement in the expression levels of tumour necrosis factor‐α (TNF‐α), interferon‐γ (IFN‐γ) and Bax genes as well as a reduction in the expression levels of transforming growth factor‐ß (TGF‐β) and Bcl2. But, shikonin treatment significantly reduced the expression levels of TNF‐α, IFN‐γ and Bax. On the other hand, the expression levels of TGF‐β and Bcl2 as well as the activity of glutathione peroxidase‐1 (GPX‐1) enzyme were significantly increased following the shikonin treatment. Conclusions This study emphasized the immune‐modulatory and antioxidative effects of shikonin, which may have an important healing effect on the severity of EAE.